![Erik Schropp](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Erik Schropp
Directeur/Membre du Conseil chez
POLYPEPTIDE GROUP AG
Fortune : 154 879 $ au 31/05/2026
Profil
Erik Schropp currently works at C&P Investors Ltd., as Chief Executive Officer from 2020, Esperante Investments S.
r.l., as Chief Executive Officer from 2020, Haydn Holding AB, as Director from 2012, PolyPeptide Group AG, as Non-Executive Director from 2021, SEVER Life Sciences BV, as Director from 2019, Draupnir Holding BV, as Director from 2008, and Ferring Foundation BV, as Director from 2008.
Mr. Schropp also formerly worked at Ferring Pharmaceuticals A, as Director-International Tax & Finance from 1999 to 2005, Altacor Ltd., as Director from 2014 to 2017, PolyPeptide Laboratories Holding BV, as Director from 2017 to 2021, PolyPeptide Laboratories Holding (PPL) AB, as Director from 2017 to 2021, FinVector Oy, as Director from 2020 to 2021, Unisource NV, as Manager-International Tax from 1996 to 1999, and Arthur Andersen Accountants, as Tax Manager from 1988 to 1996.
Mr. Schropp received his graduate degree in 1988 from Erasmus University Rotterdam.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
POLYPEPTIDE GROUP AG 0,01 % | 31/12/2025 | 3 193 ( 0,01 % ) | 154 879 $ | 31/05/2026 |
Postes actifs de Erik Schropp
| Sociétés | Poste | Début |
|---|---|---|
| POLYPEPTIDE GROUP AG | Directeur/Membre du Conseil | 01/01/2021 |
C&P Investors Ltd. | Directeur Général | 01/01/2020 |
Draupnir Holding BV
 Draupnir Holding BV Miscellaneous Commercial ServicesCommercial Services Provides organizational, business and management consulting services | Directeur/Membre du Conseil | 01/01/2008 |
SEVER Life Sciences BV
 SEVER Life Sciences BV Pharmaceuticals: MajorHealth Technology Develops, manufactures, distributes and markets pharmaceutical products | Directeur/Membre du Conseil | 01/01/2019 |
Haydn Holding AB | Directeur/Membre du Conseil | 01/01/2012 |
Ferring Foundation BV
 Ferring Foundation BV Financial ConglomeratesFinance Functions as an investment holding and management company | Directeur/Membre du Conseil | 01/01/2008 |
Esperante Investments S. r.l.
 Esperante Investments S. r.l. MiscellaneousMiscellaneous Functions as an investment holding company | Directeur Général | 01/01/2020 |
Anciens postes connus de Erik Schropp
| Sociétés | Poste | Fin |
|---|---|---|
PolyPeptide Laboratories Holding BV
 PolyPeptide Laboratories Holding BV Financial ConglomeratesFinance Functions as an investment holding company | Directeur/Membre du Conseil | 01/01/2021 |
PolyPeptide Laboratories Holding (PPL) AB
 PolyPeptide Laboratories Holding (PPL) AB Financial ConglomeratesFinance Functions as an investment holding company | Directeur/Membre du Conseil | 01/01/2021 |
| ░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Erik Schropp
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
32
Relations au 1er degré
15
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 15 |
|---|---|
Unisource NV
 Unisource NV Specialty TelecommunicationsCommunications Provides telecommunication services | Communications |
Ferring Pharmaceuticals A/S
 Ferring Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Specializes in the development, production and marketing of pharmaceutical products | Health Technology |
Erasmus University Rotterdam
 Erasmus University Rotterdam Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Altacor Ltd.
 Altacor Ltd. Pharmaceuticals: MajorHealth Technology Operates as a ophthalmology company which develops and markets a portfolio of products in fields of dry eye, glaucoma & ocular infection | Health Technology |
PolyPeptide Laboratories Holding BV
PolyPeptide Laboratories Holding BV Financial ConglomeratesFinance Functions as an investment holding company | Finance |
PolyPeptide Laboratories Holding (PPL) AB
PolyPeptide Laboratories Holding (PPL) AB Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Arthur Andersen Accountants
 Arthur Andersen Accountants Miscellaneous Commercial ServicesCommercial Services Provides accounting services | Commercial Services |
Haydn Holding AB | |
C&P Investors Ltd. | |
FinVector Oy
 FinVector Oy Pharmaceuticals: MajorHealth Technology Operates as pharmaceuticals company which provides research and development services | Health Technology |
PolyPeptide Group AG
 PolyPeptide Group AG BiotechnologyHealth Technology Manufactures polypeptide and custom peptide synthesis | Health Technology |
SEVER Life Sciences BV
SEVER Life Sciences BV Pharmaceuticals: MajorHealth Technology Develops, manufactures, distributes and markets pharmaceutical products | Health Technology |
Draupnir Holding BV
Draupnir Holding BV Miscellaneous Commercial ServicesCommercial Services Provides organizational, business and management consulting services | Commercial Services |
Ferring Foundation BV
Ferring Foundation BV Financial ConglomeratesFinance Functions as an investment holding and management company | Finance |
Esperante Investments S. r.l.
Esperante Investments S. r.l. MiscellaneousMiscellaneous Functions as an investment holding company | Miscellaneous |
